Preclinical research of safety and influences on immune system of the low-dose oral allergovaccine
The efficiency and safety of allergovaccination depends on quality of allergovaccines and methods of their administration. We designed low-dose oral allergovaccine AV-2P. It comprises the complex of water-salt extract of home dust allergen, epidermal allergen and inert carrier. The purpose of the study was to assess acute and sub-acute toxicity, immunotoxicity of the new drug - low-dose oral allergovaccine AV-2P. Object of the study: laboratory animals - white Wistar rats and mice. It was proved that allergovaccine AV-2P is characterized by low toxicity. LD50 for this drug was not defined. Longitudinal administration of AV-2P didn't cause any pathological changes in animals. The vaccine was deprived of any immunotoxic effects, but demonstrated evident immunobiological activity. The obtained data proved that low-dose oral allergovaccine AV-2P is the safe and highly active immunobiological drug.